Review of epidermal growth factor receptor biology.

[1]  J. Woodburn,et al.  Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines , 2005, Breast Cancer Research and Treatment.

[2]  H. Bier,et al.  Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma , 2004, European Archives of Oto-Rhino-Laryngology.

[3]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[4]  M. Kris,et al.  O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone , 2003 .

[5]  R. Natale.  O-244 Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor , 2003 .

[6]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Vokes,et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Needle.  Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. , 2002, Seminars in oncology.

[9]  G. Fontanini,et al.  Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. Ethier,et al.  Signal transduction pathways: the molecular basis for targeted therapies. , 2002, Seminars in radiation oncology.

[11]  T. Lawrence,et al.  Small-molecule tyrosine kinase inhibitors as radiosensitizers. , 2002, Seminars in radiation oncology.

[12]  Roy S Herbst,et al.  Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.

[13]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[14]  D. Lynch,et al.  Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. , 2002, Seminars in oncology.

[15]  R. Schmidt-Ullrich,et al.  Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. , 2001, Journal of the National Cancer Institute.

[16]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.

[17]  C. Dinney,et al.  The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. , 2001, The Journal of urology.

[18]  R. Schmidt-Ullrich,et al.  The relative role of ErbB1–4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells , 2001, Oncogene.

[19]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[20]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  L. Pustilnik,et al.  Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  J. Brugge,et al.  Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.

[24]  W. Liu,et al.  Heregulin regulation of Akt/protein kinase B in breast cancer cells. , 1999, Biochemical and biophysical research communications.

[25]  P. Tsichlis,et al.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. , 1999, Annual review of biochemistry.

[26]  M. Volm,et al.  Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. , 1998, British Journal of Cancer.

[27]  G. Iliakis.  Cell cycle regulation in irradiated and nonirradiated cells. , 1997, Seminars in oncology.

[28]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[29]  J. Mendelsohn.  Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  H. Bier,et al.  Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. , 1997, Anticancer research.

[31]  L. Pustilnik,et al.  Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. , 1997, Cancer research.

[32]  K. Gibson,et al.  ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT , 1997 .

[33]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[34]  R. Fridman,et al.  Epidermal growth factor and amphiregulin up‐regulate matrix metalloproteinase‐9 (MMP‐9) in human breast cancer cells , 1997, International journal of cancer.

[35]  H. Kato,et al.  A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. , 1996, European journal of cancer.

[36]  M. Gore,et al.  Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. , 1996, British Journal of Cancer.

[37]  M Hosokawa,et al.  Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[38]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[39]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[40]  N. Rosen,et al.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. , 1995, The Journal of clinical investigation.

[41]  K. Valerie,et al.  Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. , 1994, International journal of radiation oncology, biology, physics.

[42]  K. Pavelić,et al.  Evidence for a role of EGF receptor in the progression of human lung carcinoma. , 1993, Anticancer research.

[43]  G. Gibson,et al.  The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. , 1993, British Journal of Cancer.

[44]  R. Bjerkvig,et al.  Effects of EGF, BFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain‐tumour biopsies In Vitro , 1993, International journal of cancer.

[45]  Goldman,et al.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. , 1993, Molecular biology of the cell.

[46]  R. Dickson,et al.  The EGF receptor system as a target for antitumor therapy. , 1991, Cancer investigation.

[47]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[48]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.